MedTrace Logo

Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer

NCT00551044 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2007-10-30

No results posted yet for this study

Summary

The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Bicalutamide

Bicalutamide 150mg once daily, oral administration, for 12 months

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Wirral University Teaching Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Nigel J Parr, MBBS, FRCS(Urol), MD · Wirral University Teaching Hospital NHS Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2005-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551044 on ClinicalTrials.gov